AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04883775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: MVT-5873 will be administered intravenously over at least 60 minutes.
Study NCT06407973 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: OMNI Surgical System
Description: The OMNI Surgical System is 510(k) cleared and indicated for canaloplasty (microcatheterization and transluminal viscodilation of Schlemm's canal) followed by trabeculotomy (cutting of trabecular meshwork) to reduce intraocular pressure in adult patients with primary open-angle glaucoma
Study NCT06407973 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost plus adjunctive glaucoma medication
Description: * Latanoprost ophthalmic solution (0.005%) is a topical prostaglandin F2 analog used in the treatment of Glaucoma.~* Adjunctive topical glaucoma medication(s) as selected by the Investigator
Study NCT04750226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-951
Description: Solution for continuous subcutaneous infusion (CSCI).
Study NCT05826600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMX-0407
Description: Dose escalation, Dose expansion
Study NCT05950243 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire survey for data collection
Study NCT05557123 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MEDI-app
Description: MEDI-app based feedback algorithm. The app based feedback algorithm will check and remind the patients of taking medication.
Study NCT04475393 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carmat Total Artificial Heart
Description: Heart Replacement Therapy
Study NCT06223516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) ABBV-383
Description: SC Injection
Study NCT06223516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) ABBV-383
Description: IV Infusion
Study NCT06465069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY4052031
Description: Intravenous
Study NCT06555016 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reactive balance training
Description: Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
Study NCT06555016 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Reactive balance training
Description: Reactive balance training involves clients experiencing repeated balance perturbations so that they can practice and improve control of reactions to avoid falling after a loss of balance.
Study NCT05200611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal Immunochemical Test
Description: Participants with positive fecal immunochemical test results were further examined by colonoscopy.
Study NCT05103670 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA
Description: 32 patients will undergo a Ventilation/Perfusion PET/CT with Galligas and 68Ga-MAA at the inclusion and 3 months later.
Study NCT04952402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Study-provided Moderna mRNA-1273 COVID-19 vaccine
Description: Participants received a two-dose series (100 µg (0.5 mL) was administered intramuscularly (IM) at Day 0 and Day 28).
Study NCT06555016 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Walking
Description: Overground walking.
Study NCT05949684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Specified dose on specified days
Study NCT06239532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC+TAE
Description: Procedure: HAIC+TAE After successful percutaneous hepatic artery cannulation for continuous pumping of drugs. Oxaliplatin(85 mg/m2); Raltitrexed (3 mg/m2) ，continuous infusion for 3 hours. HAIC was performed at an interval of at least 21 days.
Study NCT06239532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Drug: Tislelizumab(200 mg) will be administered by IV infusion every 3 weeks
Study NCT06239532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Drug: Surufatinib was taken orally after meals, once a day, with 3-5 capsules (50mg/capsule) each time.
Study NCT06019663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Artificial Intelligence intervention for Self-Harm prevention Application (AISHA) is a mobile intervention based on Y-CMAP
Description: YCMAP is a Youth culturally adapted manual assisted psychological intervention based on CBT principles. The therapy focuses on current problems that contributed to the self-harm episode. Therapists and adolescent clients choose from a list of techniques those which are most relevant to the client's problems. Therapy is therefore adapted to fit with the client's problems and primarily utilises problem solving, CBT, and dialectical therapy strategies to bring about change.
Study NCT04651439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Injection of ZARZIO 30 MU/0,5mL and/or ZARZIO 48 MU/0,5mL, over a period of 5 consecutive days (1 injection per day during 30 minutes - - day 1 : set up standard treatment). The filgrastim solution will be diluted in 20 mL of 5% Glucose. The dose of ZARZIO administrated depends of the patient's weight :~* 20 to \< 30kg = 0,3 mL of ZARZIO 48 MU/0,5mL (subcutaneous route)~* 30 to \< 60kg = 0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 60 to \< 90kg = 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* 90 to \< 120kg = 2x0,5 mL of ZARZIO 30 MU/0,5mL (by IV)~* 120 to 150kg = 0,5 mL of ZARZIO 30 MU/0,5mL + 0,5 mL of ZARZIO 48 MU/0,5mL (by IV)~* > 150kg = 2x0,5 mL of ZARZIO 48 MU/0,5mL (by IV)
Study NCT04651439 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injection of 20 mL of Glucose 5% solution over a period of 5 consecutive days (1 injection per day during 30 minutes - day 1 : set up standard treatment). The dose given is equivalent to that used for filgrastim :~* 20 to \< 30kg = placebo not available because the injection must be done subcutaneously so the blind cannot be respected.~* 30 to \< 60kg = 20mL of Glucose 5% solution (by IV)~* 60 to \< 90kg = 20mL of Glucose 5% solution (by IV)~* 90 to \< 120kg = 20mL of Glucose 5% solution (by IV)~* 120 to 150kg = 20mL of Glucose 5% solution (by IV)~* > 150kg = 20mL of Glucose 5% solution (by IV)
Study NCT06358664 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pars plana vitrectomy
Description: Standard pars plana vitrectomy will be performed
Study NCT05949684 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Epoetin Alfa
Description: Specified dose on specified days
Study NCT06077955 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mini-gastric bypass with stapled anastomosis
Description: the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a linear stapler.
Study NCT06077955 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mini-gastric bypass with hand-sewn anastomosis
Description: the stomach is transected using linear endoscopic staplers in such a way as to create an isolated narrow gastric tube (small ventricle) at least 17-18 cm long and 15-20 mm wide (diameter of gastric tube used 36-39 Fr). • A gastroenterostomy is performed at a distance of 150-200 cm from the ligament of Treitz using a fully manual suture.
Study NCT04730869 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Treatment Plus Metabolic Therapy Program
Description: See description under Arms.
Study NCT06265792 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
Study NCT06265792 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: routine rehabilitation treatment
Description: All participants were given routine rehabilitation treatment by professional rehabilitation therapists, including exercise therapy, guided education, psychological therapy, acupuncture and massage therapy
Study NCT06265792 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The patients were provided with Stellate ganglion block , using 0.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study NCT05096234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [ 18F]F-AraG PET
Description: Dose: 5 mCi (±10%) Mode of Administration: Intravenous (IV)
Study NCT06636318 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample Collection
Description: To characterize the phenotype and function of immune cells in surgery residents before and after a 24-hour shift, and before and after a month of being on call. Along with to investigate the relationship between sleep deprivation, physical activity, and different immune responses.
Study NCT06636318 — intervention group
Intervention type: DEVICE
Intervention: Actigraph (GT9X-BT) Monitor
Description: Participants will be asked to wear their monitor every day for a week. The monitor will collect their step count, sleep and heart rate automatically. Participants will return their monitor at visit 5 (day 30) of the study.
Study NCT05947461 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100mg diclofenac
Description: All patients without contraindications should receive 100mg rectal diclofenac 30mins before ERCP procedure
Study NCT05947461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 100mg indomethacin
Description: All patients without contraindications should receive 100mg rectal indomethacin 30mins before ERCP procedure
Study NCT04867512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Liquid Tincture
Description: Biocidin Liquid Tincture: 1 drop by mouth twice daily, increased by one drop each day until 15 drops twice daily have been reached. 15 drops by mouth twice daily will be maintained through the duration of the study.
Study NCT04867512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: GI Detox
Description: GI Detox: 2 capsules by mouth every evening and 1 hour away from all food maintained through the duration of the study.
Study NCT04867512 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olivirex
Description: Olivirex: 2 capsules by mouth twice daily taken with Biocidin liquid tincture starting at week 10 until week 14 of the study for non-responders determined by symptoms and lactulose breath test results.
Study NCT05352516 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HLX14
Description: Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of HLX14 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects will be continue with a third dose of HLX14.
Study NCT05352516 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolia®
Description: Subjects will receive a total of 3 doses of subcutaneous injection of HLX14 or Prolia® (once every 6 months (Q6M)).~Treatment period 1: D1-D364, subjects will receive subcutaneous injection of Prolia® 60mg on D1 and D183.~Treatment period 2: D365-D546, on D365, subjects in the Prolia® arm will be re-randomized 1:1 to either continue with a third dose of Prolia® or transition to HLX14 and receive a single dose of HLX14.
Study NCT04952402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Community-provided Moderna mRNA-1273 COVID-19 Vaccine
Description: Participants received a two-dose series.
Study NCT04952402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
Description: Participants received a two-dose series.
Study NCT04875767 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)
Description: General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.
Study NCT04875767 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HA-based scaffold with BMA (Hyalofast®; Anika Therapeutics, Bedford, MA, USA)
Description: General surgical and anaesthetic risks apply to the subjects included in the trial. Microfracture and BMA are surgical techniques currently being used and are approved for use in Canada. The HA-scaffold that will be used in this trial (Hyalofast®, Anika Therapeutics Inc.) has European CE Mark for use in all joints. We will obtain a Health Canada approval to use the Hyalofast® product in the hip for this trial.
Study NCT05956093 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FAPI PET CT
Description: the utilization of Gallium 68 labelled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET/CT to accurately stage high-grade epithelial ovarian cancers.
Study NCT06075511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6 minutes walk distance
Description: Subjects walk as far as possible for 6 minutes at a self-selected pace, and the total distance walked will be recorded
Study NCT06075511 — intervention group
Intervention type: BEHAVIORAL
Intervention: Activity Monitor
Description: Subjects will wear an Actigraph on their wrist like a watch for up to 10 days at home to monitor activity.
Study NCT06075511 — intervention group
Intervention type: BEHAVIORAL
Intervention: Continuous Glucose Monitor
Description: Subjects will collect glucose values in the fluid under their skin for up to 10 days at home.
Study NCT06075511 — intervention group
Intervention type: BEHAVIORAL
Intervention: Blood Pressure Monitoring
Description: Subjects will monitor their blood pressure at home for 10 consecutive days 3 times a day
Study NCT06075511 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Pressure Monitoring
Description: 24-hour ambulatory blood pressure monitoring
Study NCT06379178 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral colostrum application 2 hours
Description: Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 2 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
Study NCT06379178 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Oral colostrum application 4 hours
Description: Oral colostrum application is an intervention to apply colostrum to oral cavity of subjects. This arm is given oral colostrum application every 4 hours. Colostrum must be from the breastmilk of subject's mother and donor breastmilk is not allowed. Colostrum is treated according to the standard operating procedure of breastmilk storage and preparation of RSUP Dr. Sardjito.
Study NCT06071130 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Strong
Description: Procedure: During Years 3-5, participants will be recruited in waves through our standard recruitment practices to participate in Experiments 4A at the City of Chicago park sites. We will first prescreen them via telephone to verify that potential participants meet the inclusion criteria. F\&S! classes will be offered at two pre-determined Chicago park sites. Each of the two sites will host the 8-week-long program once in the spring and once in the fall for two years for a total of four F\&S! cycles at each center (totaling 8 F\&S! cohorts). Upon consenting to be in E4A, participants will be enrolled in F\&S! at the site closest to their home or the wait-list control. In the pre-intervention phase, participants both in F\&S! and on the waitlist will come to the lab at DePaul to complete the pre-intervention measurement batter. Within one week after baseline measurements, participants will attend F\&S! for 3 sessions a week for 8 weeks.
Study NCT06552546 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icodextrin
Description: Eligible participants were admitted to the hosptial ward and used one icodextrin bag (single-dose icodextrin) or two icodextrin bags (double-dose icodextrin) on the first day, depending on their choice. Each icodextrin solution was left in the peritoneal cavity for a 8-hour dwell. The double-dose icodextrin was administered in a sequential way. After the icodextrin exchange(s), the solution was drained from the peritoneal cavity and the patients resumed dialysis using dextrose dialysate with two or three additional manual exchanges performed for the balance of the 24 hours since the icodextrin dwell was initiated. Patients were discharged and requested to return on days 7 and 14. Blood, urine and dialysate samples are collected at the time-points as required. Icodextrin and metabolites were analyzed and the pharmacokinetics profiles of single- and double-dose icodextrin were provided.
Study NCT06141109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab 200mg+MB07133 600mg
Description: 1. Adopting the classic 3+3 scheme design, 3 dose groups, with a cycle of 21 days. On the first day of each cycle, a single infusion of Sintilimab is given, and MB07133 is given for 7 consecutive days after a 2-hour interval between infusion initiation.~2. Sintilimab 200mg+MB07133 1800mg, recruiting 30 subjects，the administration method is as 1.
Study NCT05725967 — intervention group
Intervention type: PROCEDURE
Intervention: Primary Obesity Endoscopic Procedures
Description: Any primary endoscopic procedure for treatment of obesity including endoscopic sleeve gastroplasty (ESG), intragastric balloons (IGB), Aspiration therapy, pylorus sparing antral myotomy (PSAM), primary obesity surgery endoluminal (POSE), gastroplasty with endoscopic myotomy (GEM).
Study NCT05725967 — intervention group
Intervention type: PROCEDURE
Intervention: Endoscopic Revision of Bariatric Surgical Procedures
Description: Any endoscopic revision procedure in a post-bariatric surgical patient, including transoral outlet reduction (TORe), restorative obesity surgery endoluminal (ROSE), argon plasma coagulation of the outlet (APC), endoscopic suturing.
Study NCT05725967 — intervention group
Intervention type: PROCEDURE
Intervention: Bariatric Surgery Procedures
Description: Any bariatric surgical procedure including Roux-en-Y gastric bypass (RYGB), laparoscopic sleeve gastroplasty (LSG), laparoscopic adjustable gastric banding (LAGB)
Study NCT05725967 — intervention group
Intervention type: DEVICE
Intervention: Endoscopic Sleeve Gastroplasty, Trans-oral Outlet Reduction
Description: Any endoscopic procedure using an endoscopic suturing device for primary obesity treatment or revision of post bariatric complications.
Study NCT05725967 — intervention group
Intervention type: DEVICE
Intervention: Intragastric Balloon
Description: An endoscopic bariatric procedure involving the placement of an intragastric balloon.
Study NCT05725967 — intervention group
Intervention type: DEVICE
Intervention: Primary obesity surgery endoluminal, Restorative obesity surgery endoluminal
Description: Any endoscopic procedure using an endoscopic plicating device for primary obesity treatment or revision of post bariatric complications.
Study NCT06264869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)
Description: Interdental guided creeping technique (IGCT) and connective tissue graft (CTG)
Study NCT06264869 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interdental guided creeping technique (IGCT) and collagen membrane (CM)
Description: Interdental guided creeping technique (IGCT) and collagen membrane (CM)
Study NCT05986305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Go Act
Description: Go Act sessions address becoming a parent who can 'Go Act,' caring for one's self as a parent, understanding and managing youth health needs, working with health providers as partners, and working with other service providers such as schools and vocational services. The intervention uses motivational interviewing, story-telling with self-disclosure, psycho-education introduced with a know-want to know-learned strategy, problem-solving, role play, and practice outside of class.
Study NCT05986305 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer
Description: During Peer sessions facilitators lay ground rules for respectful and confidential sharing and encourage group discussion. The group provides a format to make personal connections through shared identity. Participants may discuss strategies for individualized advocacy, so that they learn from the experiences of others.
Study NCT04847375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exogenous surfactant
Description: Nebulized Surfactant would be administered by face mask which has a nebulizer